Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase III trials in patients with type 2 diabetes.
        
Representative scheme of DPP4N_Peptidase_S9 structure and an image from PDBsum server
no Image
Databases
PDB-Sum
2ONC Previously Class, Architecture, Topology and Homologous superfamily - PDB-Sum server
FSSP
2ONCFold classification based on Structure-Structure alignment of Proteins - FSSP server